A combination of two cancer-fighting drugs that block two common cancer pathways is showing promise in an early-stage study, according to Genentech Inc.
The South San Francisco-based U.S. arm of Swiss drug maker Roche said at the American Association for Cancer Research conference in Orlando, Fla., this weekend that a combination of the experimental drugs GDC-0973 and GDC-0941 is being tested in a 27-patient study. Several patients saw decreased tumor size, Genentech said, and three others found that their disease stabilized over six months.
No comments:
Post a Comment